Cantor Fitzgerald Brokers Lift Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Aquestive Therapeutics in a note issued to investors on Tuesday, August 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings of ($0.56) per share for the year, up from their previous estimate of ($0.64). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share. Cantor Fitzgerald also issued estimates for Aquestive Therapeutics’ FY2026 earnings at ($0.57) EPS.

Several other brokerages have also commented on AQST. Zacks Research upgraded shares of Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Finally, Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, June 2nd. They set an “outperform” rating and a $7.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Aquestive Therapeutics Trading Up 0.8%

Aquestive Therapeutics stock opened at $3.91 on Thursday. The stock has a market cap of $389.91 million, a P/E ratio of -5.59 and a beta of 1.99. The company has a fifty day simple moving average of $3.81 and a 200-day simple moving average of $3.17. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Aquestive Therapeutics by 6.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after purchasing an additional 2,649 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Aquestive Therapeutics by 16.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after acquiring an additional 3,821 shares during the period. MetLife Investment Management LLC increased its stake in shares of Aquestive Therapeutics by 11.4% during the fourth quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock worth $143,000 after acquiring an additional 4,125 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Aquestive Therapeutics by 16.6% during the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock worth $106,000 after acquiring an additional 4,557 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.